Subgroup Observations From Missed KEYNOTE-789 Data in NSCLC Provide Insight for the Future
September 4th 2023
James Chih-Hsin Yang, MD, PhD, discusses the implications of the phase 3 KEYNOTE-789 trial and what directions investigators can examine in the future to help fill the unmet need for patients with TKI-resistant, EGFR-mutated metastatic non–small cell lung cancer.